JMP Securities Reiterates Market Outperform on Benitec Biopharma, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has reiterated its Market Outperform rating for Benitec Biopharma (NASDAQ:BNTC) and maintained a price target of $16.
September 30, 2024 | 1:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating for Benitec Biopharma, maintaining a $16 price target, indicating confidence in the company's future performance.
The reiteration of a Market Outperform rating and a maintained price target of $16 by JMP Securities suggests a positive outlook for Benitec Biopharma. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100